The AE24 study observed a statistically significant association with topoisomerase II inhibitor exposure during pregnancy only in mothers of infants with MLL+ AML, but this association was not observed for infants with MLL− disease or ALL.13, 17. Here, KMT2A is linked to acute myeloid leukemia.